Scholarlink

<p>Naïve T cells maintain a delicate balance between quiescence and rapid activation, which involves multiple layers of regulation beyond transcription. Here, we identify the RNA modification N6,2’-O-dimethyladenosine (m<sup>6</sup>Am) and its methyltransferase PCIF1 as critical enforcers of T cell quiescence. During CD4<sup>+</sup> T cell activation, m<sup>6</sup>Am levels are dynamically downregulated. T-cell-specific PCIF1 knockout (cKO) mice exhibit potent tumor suppression, driven by enhanced Th1 differentiation and subsequent amplification of NK cell cytotoxicity. Mechanistically, PCIF1 represses STAT1 translation via m<sup>6</sup>Am modification of its mRNA, thereby constraining Th1 commitment. Activation-induced PCIF1 downregulation releases this translational brake, enabling rapid Th1 polarization. Crucially, we identify Suramin as a pharmacological PCIF1 inhibitor that disrupts m<sup>6</sup>Am modification, boosts Th1 responses, and suppresses tumor growth. Our findings establish the PCIF1-m<sup>6</sup>Am-STAT1 axis as a translational checkpoint governing T cell differentiation and suggest that targeting PCIF1 represents a potential strategy for tumor immunotherapy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Blocking the m6Am methyltransferase PCIF1 releases STAT1-mediated Th1 immunity to potentiate cancer immunotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月22日

查看全文
  • Jiansong Huang,
  • Jing Zhou,
  • Xiao Liu,
  • Xiaoxu Liu,
  • Ye Xiao,
  • Kai Li,
  • Chenbo Ding,
  • Xuemin Cai,
  • Wenli Mao,
  • Changfen Xu,
  • Yuxin Kong,
  • Yu Deng,
  • Xiaohan Song,
  • Mei Yang,
  • Daohai Du,
  • Siqi Guo,
  • Kaixian Chen,
  • Cheng Luo,
  • Chengqi Yi,
  • Shijie Chen,
  • Hua-Bing Li

摘要

Naïve T cells maintain a delicate balance between quiescence and rapid activation, which involves multiple layers of regulation beyond transcription. Here, we identify the RNA modification N6,2’-O-dimethyladenosine (m6Am) and its methyltransferase PCIF1 as critical enforcers of T cell quiescence. During CD4+ T cell activation, m6Am levels are dynamically downregulated. T-cell-specific PCIF1 knockout (cKO) mice exhibit potent tumor suppression, driven by enhanced Th1 differentiation and subsequent amplification of NK cell cytotoxicity. Mechanistically, PCIF1 represses STAT1 translation via m6Am modification of its mRNA, thereby constraining Th1 commitment. Activation-induced PCIF1 downregulation releases this translational brake, enabling rapid Th1 polarization. Crucially, we identify Suramin as a pharmacological PCIF1 inhibitor that disrupts m6Am modification, boosts Th1 responses, and suppresses tumor growth. Our findings establish the PCIF1-m6Am-STAT1 axis as a translational checkpoint governing T cell differentiation and suggest that targeting PCIF1 represents a potential strategy for tumor immunotherapy.